What are the main functions and effects of baricitinib?

Baricitinib (Baricitinib) is a selective Janus kinase (JAK) inhibitor that mainly regulates abnormal responses of the immune system by interfering with the JAK1 and JAK2 signaling pathways and inhibiting the conduction of inflammatory factors. This mechanism allows baricitinib to exert a broad range of effects in a variety of inflammatory and autoimmune diseases. Baricitinib was initially approved for the treatment of moderately to severely active rheumatoid arthritis, specifically in patients who have had an inadequate response to traditional antirheumatic drugs such as methotrexate. It reduces joint pain, swelling and slows the progression of joint damage, thereby improving patients' mobility and quality of life.

In addition to rheumatoid arthritis, baricitinib is also gradually playing an important role in other indications. For example, in some countries and regions, the drug has been included in investigational treatment plans for refractory autoimmune diseases such as systemic lupus erythematosus (SLE), showing its potential to inhibit immune-mediated inflammatory responses. In recent years, baricitinib has also received widespread attention in the regulation of inflammatory storms related to viral infections, especially in systemic inflammatory response syndrome caused by certain severe infections (such as severe COVID-19 infection). It has been emergency approved for use as a drug to regulate the excessive response of the immune system.

In addition, some studies are also exploring the therapeutic effect of baricitinib on skin diseases such as atopic dermatitis, alopecia areata (alopecia areata), etc. Since immune abnormalities and chronic inflammation are also part of the pathogenesis of this type of disease, baricitinib is expected to improve symptoms and slow down the course of the disease by blocking inflammatory factor signals. It is worth noting that although the drug has broad anti-inflammatory potential, the indications, dosage and treatment cycle still need to be reasonably evaluated under the guidance of a doctor to maximize the balance between efficacy and safety.

Reference materials:https://go.drugbank.com/drugs/DB11817